HUMANA INC (HUM) is held by 8 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds opening new positions, 2 funds adding, and 2 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $2.6M sold). Latest close $385.78 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 10, 2026 · Congress to Nov 16, 2026.
Sessa Capital · Slate Path Capital · Pzena Investment Management — 8 tracked funds hold HUM. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 2 sales ($2.6M). Insider trading
ALNYLAM PHARMACEUTICALS, INC. (ALNY) · BOSTON SCIENTIFIC CORP (BSX) · Shell plc (SHEL) · Elevance Health, Inc. (ELV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Sessa Capital | 24.76% | 3,727,740 | HELD Q3 filed Nov 16 |
| Slate Path Capital | 5.94% | 1,079,930 | ADDED (+134.9%) Q3 filed Nov 16 |
| Pzena Investment Management | 5.13% | 4,403,136 | TRIMMED (-19.5%) Q3 filed Oct 30 |
| Eagle Capital Management | 4.67% | 3,846,762 | ADDED (+29.6%) Q3 filed Nov 16 |
| Dodge & Cox Funds | 2.28% | 10,940,380 | TRIMMED (-3.9%) Q3 filed Nov 13 |
| OrbiMed Advisors | 1.21% | 164,100 | NEW Q3 filed Nov 16 |
| SRS Investment Management | 0.12% | 33,282 | NEW Q3 filed Nov 16 |
| Deerfield Management | <0.01% | 917 | HELD Q3 filed Nov 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +8.3% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 933 of 8,857 filers |
| Long-only filers among them | 923 |
| Change vs 2026 Q1 | +159 net · 865 entered · 706 exited |
| Shares reported, all filers | 118,030,803 |
| Reported value, all filers | $49.0B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Hospital & Medical Service Plans (SIC 6324) |
| Revenue · FY2025 | $129.7B |
| Net income · FY2025 | $1.2B |
| Total assets · FY2025 | $48.9B |
| Shares outstanding | 120,826,000 |
| Market cap (at latest close) | $46.6B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported 2025.
| Shares short · Oct 15, 2026 | 3,665,781 |
| Share of shares outstanding | 3.03% |
| Days to cover | 1.98 |
Shares short at recent settlements — Jul 31, 2026: 3.7M · Aug 14, 2026: 3.4M · Aug 31, 2026: 3.1M · Sep 15, 2026: 2.8M · Sep 30, 2026: 2.8M · Oct 15, 2026: 3.7M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of 2025.
| Shares failed to deliver · Oct 14, 2026 | 11,547 |
| Share of shares outstanding | 0.01% |
| Fails as a share of short interest · Oct 15, 2026 | 0.3% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 11 · Sep 30, 2026: 0 · Oct 14, 2026: 12K.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of 2025.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 2 sales by 2 insiders ($2.6M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Frederick Wayne A.I. | Sell | 440 | $440.57 | $193.9K | SEC filing | |
| Nov 9, 2026 | Ventura Joseph C | Chief Legal Officer | Sell | 5,495 | $433.85 | $2.4M | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Apr 8, 2025 | Diamond Susan M | Former Chief Financial Officer | 10,959 | $2.7M | Apr 8, 2025 | SEC filing |
| Feb 24, 2025 | Huval Timothy S. | Former Chief Administrative Officer | 1,247 | $322.4K | Feb 24, 2025 | SEC filing |
| Dec 31, 2024 | Huval Timothy S. | Officer | 3,703 | $938.4K | Dec 31, 2024 | SEC filing |
| Dec 6, 2024 | William K. Fleming | Officer | 8,661 | $2.5M | Dec 6, 2024 | SEC filing |
| May 16, 2023 | James J. O'Brien | Former Board of Directors | 11,425 | $6.0M | May 16, 2023 | SEC filing |
| May 4, 2023 | Diamond Susan M | Officer | 4,156 | $2.2M | May 4, 2023 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| May 14, 2026 | Dodge & Cox | SC 13G/A | 11,380,673 | 9.5% | Mar 31, 2026 | SEC filing |
| Apr 30, 2026 | Vanguard Capital Management | SC 13G | 9,068,300 | 7.5% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Jul 29, 2025 | The Vanguard Group | SC 13G/A | 14,199,071 | 11.8% | Jun 30, 2025 | SEC filing |
| Apr 17, 2025 | BlackRock, Inc. | SC 13G/A | 9,309,848 | 7.7% | Mar 31, 2025 | SEC filing |
| Feb 13, 2025 | Dodge & Cox | SC 13G | 10,198,040 | 8.5% | Dec 31, 2024 | SEC filing |
| Jan 8, 2025 | The Vanguard Group | SC 13G/A | 12,829,185 | 10.7% | Dec 31, 2024 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Hospital & Medical Service Plans (SIC 6324). Standing committees with jurisdiction over this industry: House Committee on Financial Services, Senate Committee on Banking, Housing, and Urban Affairs.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 210 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (130), Medicare/Medicaid (130), Defense (78).
Federal contracts: $26.1B in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $7.2B |
| FY2022 | $7.8B |
| FY2023 | $7.9B |
| FY2024 | $3.2B |
| FY2025 | $0 |
| FY2026 | $0 |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| W81K0421P3004 | Department of Defense | $8.7M | Jun 29, 2021 |
| W81K0420C0004 | Department of Defense | $6.9M | Apr 1, 2020 |
| W81K0011F0140 | Department of Defense | $3.3M | Oct 1, 2011 |
| W91YU015P0604 | Department of Defense | $521.3K | Sep 4, 2015 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Financial Screens
· Growth — Revenue up every year for 5 straight years
· Graham — Sound finances and a long run of profits
· Dividend Growth — Dividends raised for more than 10 years
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Earnings Stability — Small earnings swings and almost no loss years
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· 52-Week High — Recently printed a new 52-week high
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Growth — Latest revenue: $129.7B · 5-yr revenue CAGR: 10.9% · Straight growth years: 8
· Graham — Current ratio: 2.00 · Straight profitable years: 19 · Debt ratio: 1.77 · Latest net income: $1.2B
· Dividend Growth — Dividend per share: 3.54 · Dividend yield: 0.9% · Straight dividend years: 14 · 10-yr dividend growth: 205.2%
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.61 · Operating cash flow: $921.0M · Net income: $1.2B
· Earnings Stability — Earnings variation (CV): 0.40 · Loss years (of 10): 0 · Latest net income: $1.2B
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Politician BEST — appeared in 1 of the last 20 quarterly lists; latest 2025 Q3, ranked #12 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 5 | 60.0% | -4.6% | +4.1% | -8.7% |
| Share count tripled (3x) | 4 | 50.0% | -6.0% | +2.1% | -8.1% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold HUM — ranked by lift, the co-holding pattern described in Methodology: ALNYLAM PHARMACEUTICALS, INC. (ALNY) · BOSTON SCIENTIFIC CORP (BSX) · Shell plc (SHEL) · Elevance Health, Inc. (ELV) · BRISTOL MYERS SQUIBB CO (BMY) · COMCAST CORP (CMCSA) · GE Vernova Inc. (GEV) · GENERAL ELECTRIC CO (GE).
Filings audit: every filing lens on HUMANA INC (HUM), scored — GetCoattail Research.
| Filed | Items | Source |
|---|---|---|
| Nov 17, 2026 | 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
| Nov 9, 2026 | 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
| Nov 6, 2026 | 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) · Filings audit: every filing lens on HUMANA INC (HUM), scored · Practice timing on HUM
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.